1. Adams D., Suhr O.B., Hund E. et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016;29(1):S14–26. PMID: 26734952. DOI: 10.1097/wco.0000000000000289 2. Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021; 268(6):2109-2122. doi: 10.1007/s00415- 019-09688-0. PMID: 31907599; PMCID: PMC8179912. 3. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, PlantéBordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. doi: 10.1186/1750-1172- 8-31. PMID: 23425518; PMCID: PMC3584981. 4. Никитин С.С., Бардаков С.Н., Супонева Н.А. и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией. Нервномышечные болезни 2021;11(3):12–36. DOI: 10.17650/2222-8721-2021-11-3-12-36. 5. Лысенко (Козловская) Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клин фармакол тер 2020;29(1):13-24 [Lysenko (Kozlovskaya) LV, Rameev VV, Moiseev S, et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Therapy 2020;29(1):13-24 (In Russ.)]. DOI 10.32756/ 0869-5490-2020-1-13-24. 6. Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, ClergetDarpoux F, Misrahi M, Said G, Bonaiti-Pellie C (2003) Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 40:e120 7. Ueda M. Transthyretin: Its function and amyloid formation. Neurochem Int. 2022 May;155:105313. doi: 10.1016/j.neuint.2022.105313. Epub 2022 Feb 23. PMID: 35218869. 8. Yamashita T, Ueda M, Misumi Y, Masuda T, Nomura T, Tasaki M, Takamatsu K, Sasada K, Obayashi K, Matsui H, Ando Y (2018) Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a singlereferral center in Japan. J Neurol 265:134–140 9. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15:181–186 10. Зиновьева О.Е., Сафиулина Э.И. Транстиретиновая амилоидная полинейропатия: патогенез, клинические особенности, перспективы лечения. Manage pain. 2017; 4: 12– 5. / Zinov'eva O.E., Safiulina E.I. Transtiretinovaia amiloidnaia polineiropatiia: patogenez, klinicheskie osobennosti, perspektivy lecheniia. Manage pain. 2017; 4: 12–5. [in Russian] 11. Адян Т.А., Поляков А.В. Наследственный транстиретиновый амилоидоз. Нервномышечные болезни. 2019;9(4):12-25. DOI:10.17650/2222-8721-2019-9-4-12-25 12. Mariani LL, Lozeron P, Theaudin M et al (2015) Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901– 916 13. Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, Stewart M, Fallet S, Amass L. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018 May;57(5):829-837. doi: 10.1002/mus.26034. Epub 2018 Feb 1. PMID: 29211930; PMCID: PMC5947118. 14. Inês M, Coelho T, Conceição I, Duarte-Ramos F, de Carvalho M, Costa J. Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study. Neuroepidemiology. 2018;51(3-4):177-182. doi: 10.1159/000490553. Epub 2018 Aug 28. PMID: 30153683. 31 15. Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):17-26. doi: 10.14797/mdcvj.1066. PMID: 35414855; PMCID: PMC8932385. 16. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G (2002) Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 59:1771–1776 17. Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, Shibata-Hamaguchi A, Furukawa Y, Yanase D, Ishida C, Sakajiri K, Yamada M. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci. 2008 Jul 15;270(1-2):133-40. doi: 10.1016/j.jns.2008.02.019. Epub 2008 Apr 14. PMID: 18410945. 18. Munar-Qués M, Saraiva MJ, Viader-Farré C, Zabay-Becerril JM, Mulet-Ferrer J. Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid. 2005 Mar;12(1):54-61. doi: 10.1080/13506120500032741. PMID: 16076612. 19. Dardiotis E, Koutsou P, Papanicolaou EZ, Vonta I, Kladi A, Vassilopoulos D, Hadjigeorgiou G, Christodoulou K, Kyriakides T. Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid. 2009 Mar;16(1):32-7. doi: 10.1080/13506120802676948. PMID: 19291512. 20. Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55:323–332 21. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R. Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int. 2022 Jan 12;13:12. doi: 10.25259/SNI_1235_2021. PMID: 35127212; PMCID: PMC8813631. 22. Barge-Caballero G, Barge-Caballero E, López-Pérez M, Bilbao-Quesada R, GonzálezBabarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, González-Juanatey C, Díaz-Castro Ó, Crespo-Leiro MG. Cardiac amyloidosis: Description of a series of 143 cases. Med Clin (Barc). 2022 Jan 4:S0025-7753(21)00672-2. English, Spanish. doi: 10.1016/j.medcli.2021.10.018. Epub ahead of print. PMID: 34996625. 23. Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB (2014) THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis 9:61 24. Beirao JM, Malheiro J, Lemos C, Beirao I, Costa P, Torres P (2015) Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid 22:117–122 25. Martins AC, Rosa AM, Costa E, Tavares C, Quadrado MJ, Murta JN (2015) Ocular manifestations and therapeutic options in patients with familial amyloid polyneuropathy: a systematic review. BioMed Res Int 2015:282405 26. Patil NS, Iqbal MM, Bursztyn LLCD. Conjunctival lymphangiectasia and retinal angiopathy in hereditary transthyretin amyloidosis. Int J Retina Vitreous. 2022 Jan 6;8(1):4. doi: 10.1186/s40942-021-00357-x. PMID: 34991732; PMCID: PMC8734248. 27. Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) "Red-fag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21:5–9 28. Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T, European Network for T-F (2016) Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 29(Suppl 1):S27–S35 29. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. doi: 10.1093/brain/awn093. Epub 2008 Jun 4. PMID: 18524793; PMCID: PMC2442424. 32 30. Lobato L, Beirao I, Silva M, Bravo F, Silvestre F, Guimaraes S, Sousa A, Noel LH, Sequeiros J (2003) Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant 18:532–538 31. Papagianni A, Ihne S, Zeller D, Morbach C, Üçeyler N, Sommer C. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTRamyloidosis: impact on patient management and new insights in wild-type. Amyloid. 2022 Mar;29(1):14-22. doi: 10.1080/13506129.2021.1976751. Epub 2021 Oct 11. PMID: 34632904. 32. Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M (2001) Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 51:476–480 33. Ikeda SI (2013) Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis. Brain Nerve 65:831–842 34. Andrews JPM, Trivieri MG, Everett R, Spath N, MacNaught G, Moss AJ, Doris MK, Pawade T, van Beek EJR, Lucatelli C, Newby DE, Robson P, Fayad ZA, Dweck MR. 18Ffluoride PET/MR in cardiac amyloid: A comparison study with aortic stenosis and age- and sex-matched controls. J Nucl Cardiol. 2022 Apr;29(2):741-749. doi: 10.1007/s12350-020- 02356-1. Epub 2020 Sep 30. PMID: 33000405; PMCID: PMC8993737. 35. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F (2011) Role of (99m)TcDPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imag 4:659–670 36. Uusitalo V, Suomalainen O, Loimaala A, Mätzke S, Heliö T. Prognostic Value of 99mTcHMDP Scintigraphy in Elderly Patients With Chronic Heart Failure. Heart Lung Circ. 2022 May;31(5):629-637. doi: 10.1016/j.hlc.2021.11.018. Epub 2022 Jan 19. PMID: 35063379. 37. Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, DeLuca A, Kontak A, Jin Z, Maurer MS. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol. 2018 Feb;25(1):181-190. doi: 10.1007/s12350-016-0610-4. Epub 2016 Aug 31. Erratum in: J Nucl Cardiol. 2016 Sep 20;: PMID: 27580616. 38. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016 Nov 1;1(8):880-889. doi: 10.1001/jamacardio.2016.2839. PMID: 27557400. 39. Fenoglio R, Baldovino S, Barreca A, Bottasso E, Sciascia S, Sbaiz L, Papotti M, Roccatello D. Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease. Nephron. 2022 Mar 18:1-8. doi: 10.1159/000522370. Epub ahead of print. PMID: 35307708. 40. Treviño-Herrera AB, Bustamante-Vargas AP, Lisker-Cervantes A, Ríos Y Valles Valles D, Villanueva-Mendoza C, González-Duarte A, Concha-Del-Río LE. Vitreous involvement as initial presentation of hereditary transthyretin amyloidosis related to the rare TTR Ile107Met (p.Ile127Met) pathogenic variant. Ophthalmic Genet. 2022 Jan 17:1-7. doi: 10.1080/13816810.2022.2025606. Epub ahead of print. PMID: 35038954. 41. Zampiccoli E, Barthelmes J, Kreysing L, Nägele MP, Nebunu D, Haider T, von Eckardstein A, Gerber B, Schwotzer R, Ruschitzka F, Sudano I, Flammer AJ. Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis. ESC Heart Fail. 2022 Apr;9(2):1186-1194. doi: 10.1002/ehf2.13792. Epub 2022 Jan 21. PMID: 35060356; PMCID: PMC8934987. 42. Dale Z, Chandrashekar P, Al-Rashdan L, Gill S, Elman M, Fischer KL, Nazer B, Masri A. Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in 33 transthyretin cardiac amyloidosis. Int J Cardiol. 2022 Apr 18:S0167-5273(22)00559-9. doi: 10.1016/j.ijcard.2022.04.045. Epub ahead of print. PMID: 35439584. 43. Hasegawa K, Uzui H, Fukuoka Y, Miyanaga D, Shiomi Y, Tama N, Ikeda H, Ishida K, Miyazaki S, Sekijima Y, Naiki H, Tada H. Abdominal Fat Pad Fine-Needle Aspiration for Diagnosis of Cardiac Amyloidosis in Patients with Non-Ischemic Cardiomyopathy. Int Heart J. 2022;63(1):49-55. doi: 10.1536/ihj.21-430. PMID: 35095076. 44. Do Amaral B, Coelho T, Sousa A, Guimaraes A (2009) Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid 16:232–238 45. Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018 Mar;25(3):464-468. doi: 10.1111/ene.13510. Epub 2017 Dec 26. PMID: 29115008; PMCID: PMC5838526. 46. Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017 Sep;24(3):194-204. doi: 10.1080/13506129.2017.1357545. Epub 2017 Jul 31. PMID: 28758793. 47. Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016 Sep;23(3):178-183. doi: 10.1080/13506129.2016.1207163. Epub 2016 Aug 5. PMID: 27494299; PMCID: PMC5359776. 48. Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y, Morita H, Machii K, Ohta M, Takata A, Ikeda S. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. J Neurol Sci. 2016 Mar 15;362:266-71. doi: 10.1016/j.jns.2016.01.046. Epub 2016 Jan 22. PMID: 26944161. 49. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012 Aug 21;79(8):785-92. doi: 10.1212/WNL.0b013e3182661eb1. Epub 2012 Jul 25. PMID: 22843282; PMCID: PMC4098875. 50. Merkies IS. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2013 Apr 9;80(15):1444-5. doi: 10.1212/01.wnl.0000429338.33391.87. PMID: 23569001. 51. Merlini G., Plante-Bordeneuve V., Judge D.P. et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013;6:1011–20. PMID: 24101373. DOI: 10.1007/s12265-013- 9512-x. 86. Coelho T., Ines M., Conceicao I. et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 2018;91(21): e1999– 2009. PMID: 30333157. DOI: 10.1212/WNL.0000000000006543. 52. Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20. PMID: 34923848; PMCID: PMC8763250. 53. Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Sultan MB, Maurer MS. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. Future Cardiol. 2022 Mar;18(3):165-172. doi: 10.2217/fca-2021-0095. Epub 2021 Nov 15. PMID: 34779246. 34 54. Tschöpe C, Elsanhoury A. Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges. J Clin Med. 2022 Apr 12;11(8):2148. doi: 10.3390/jcm11082148. PMID: 35456241; PMCID: PMC9031576. 55. Plumadore E, Lombardo L, Cabral KP. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis. Am J Health Syst Pharm. 2022 Jan 5;79(2):52-62. doi: 10.1093/ajhp/zxab356. PMID: 34491302. 56. Singh BM, Bohara N, Gautam K, Basnet M, Kc S, Kc B, Raut A, Phudong A, Gautam J. A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Cureus. 2021 Sep 23;13(9):e18221. doi: 10.7759/cureus.18221. PMID: 34703707; PMCID: PMC8541744. 57. Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy. Ann Pharmacother. 2020 May;54(5):470-477. doi: 10.1177/1060028019888489. Epub 2019 Nov 18. PMID: 31735059. 58. Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circ Heart Fail. 2017 Jun;10(6):e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815. PMID: 28611125. 59. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12. PMID: 33070419; PMCID: PMC8048553. 60. Carvalho A., Rocha A., Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 2015;21:282–92. PMID: 25482846. DOI: 10.1002/lt.24058. 61. Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Soderdahl G, Wikstrom L, Ando Y, Suhr OB, Ericzon BG (2007) Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 7:2597–2604 62. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, Nakamura M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M (2012) Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 78:637– 643 63. Tashima K, Ando Y, Terazaki H, Yoshimatsu S-i, Suhr OB, Obayashi K, Yamashita T, Ando E, Uchino M, Ando M (1999) Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 171:19–23 64. Ikeda S., Takei Y., Hashikura Y. Liver transplantation as treatment for neurological disorders. Expert Rev Neurother 2003;3:547–55. PMID: 19810938. DOI: 10.1586/14737175.3.4.547. 65. Hornsten R., Wiklund U., Olofsson B.O. et al. Liver transplantation does not prevent the development of lifethreatening arrhythmia in familial amyloidotic polyneuropathy, Portuguesetype (ATTR Val30Met) patients. Transplantation 2004;78:112–6. PMID: 15257048. DOI: 10.1097/01.tp.0000133517.20972.27. 66. Cruccua G., Sommer C. et al. EFNS guidelines on neuropathic pain assessment: revised 2009. European Journal of Neurology 2010, 17: 1010–1018. 67. Barge-Caballero G, Barge-Caballero E, López-Pérez M, Bilbao-Quesada R, GonzálezBabarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, González-Juanatey C, Díaz-Castro Ó, Crespo-Leiro MG. Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy. Mayo Clin Proc. 2022 35 Feb;97(2):261-273. doi: 10.1016/j.mayocp.2021.08.006. Epub 2021 Nov 19. PMID: 34802727. 68. В соответствии с приказом Министерства здравоохранения РФ от 31 мая 2021 г. № 557н «Об утверждении классификации природных лечебных ресурсов, медицинских показаний и противопоказаний к их применению в лечебно-профилактических целях». 69. Приказ Министерства здравоохранения Российской Федерации от 31 июля 2020 г. № 788н "Об утверждении Порядка организации медицинской реабилитации взрослых". 70. Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L (2017) Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 88:457– 458 71. Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Theaudin M, Adam C, Arnulf B, Adams D (2018) Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 91:e143–e152 72. Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM (2012) Amyloid neuropathy mimicking chronic infammatory demyelinating polyneuropathy. Muscle Nerve 45:26–31